MALDI-TOF mass spectrometry proteomic profiling to discriminate response to the combination of bevacizumab and erlotinib in non-small cell lung cancer (NSCLC).

被引：0
|
作者：
Salmon, JS
Sandler, A
Billheimer, D
Herbst, RS
Tran, HT
Tsao, A
Dang, TP
机构：
[1] Vanderbilt Univ Sch Med, Nashville, TN USA
[2] MD Anderson Canc Ctr, Houston, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：626S / 626S
页数：1
相关论文
共 50 条
  • [21] Intact cell MALDI-TOF mass spectrometry, a promising proteomic profiling method in farm animal clinical and reproduction research
    Soler, Laura
    Uzbekova, Svetlana
    Blesbois, Elisabeth
    Druart, Xavier
    Labas, Valerie
    THERIOGENOLOGY, 2020, 150 : 113 - 121
  • [22] Combination of quinacrine and erlotinib overcomes resistance to erlotinib in non-small cell lung cancer
    Dermavvan, Josephine Kam Tai
    Gurova, Katerina
    Pink, John
    Dowlati, Afshin
    De, Sarmishtha
    Naria, Goutham
    Sharma, Neelesh
    Stark, George
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [23] A randomized phase II trial of erlotinib or erlotinib and bevacizumab in patients with advanced EGFR mutant non-small cell lung cancer (NSCLC)
    Stinchcombe, T. E.
    Janne, P. A.
    Wang, X.
    Bertino, E. M.
    Weiss, J. M.
    Bazhenova, L.
    Gu, L.
    Lau, C. J.
    Paweletz, C. P.
    Jaslowski, A. J.
    Gerstner, G. J.
    Baggstrom, M. Q.
    Graziano, S. L.
    Beardenlii, J.
    Vokes, E. E.
    ANNALS OF ONCOLOGY, 2018, 29 : 522 - 522
  • [24] Identification of signaling pathways active in small cell lung cancer (SCLC) compared to non-small cell lung cancer (NSCLC) by proteomic profiling
    Byers, Lauren Averett
    Wang, Jing
    Yordy, John
    Fan, You-Hong
    Girl, Uma
    Shen, Li
    Wistuba, Ignacio
    Girard, Luc
    Coombes, Kevin
    Weinstein, John
    Minna, John
    Heymach, John
    CANCER RESEARCH, 2010, 70
  • [25] Identification of signaling pathways active in small cell lung cancer (SCLC) compared to non-small cell lung cancer (NSCLC) by proteomic profiling
    Byers, Lauren Averett
    Wang, Jing
    Yordy, John
    Fan, You-Hong
    Giri, Uma
    Shen, Li
    Wistuba, Ignacio
    Girard, Luc
    Coombes, Kevin
    Weinstein, John
    Minna, John
    Heymach, John
    CANCER RESEARCH, 2010, 70
  • [26] Proteomic profiling of biomarkers by MALDI-TOF mass spectrometry for the diagnosis of tracheobronchial stenosis after tracheobronchial tuberculosis
    Peng, Bihao
    Qiu, Xiaojian
    Dong, Zhiwu
    Zhang, Jie
    Pei, Yinghua
    Wang, Ting
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2021, 21 (01)
  • [27] EGFR Exon-Level Biomarkers of the Response to Bevacizumab/Erlotinib in Non-Small Cell Lung Cancer
    Baty, Florent
    Rothschild, Sacha
    Frueh, Martin
    Betticher, Daniel
    Droege, Cornelia
    Cathomas, Richard
    Rauch, Daniel
    Gautschi, Oliver
    Bubendorf, Lukas
    Crowe, Susanne
    Zappa, Francesco
    Pless, Miklos
    Brutsche, Martin
    PLOS ONE, 2013, 8 (09):
  • [28] VeriStrat® classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab
    Carbone, David P.
    Salmon, J. Stuart
    Billheimer, Dean
    Chen, Heidi
    Sandler, Alan
    Roder, Heinrich
    Roder, Joanna
    Tsypin, Maxim
    Herbst, Roy S.
    Tsao, Anne S.
    Tran, Hai T.
    Dang, Thao P.
    LUNG CANCER, 2010, 69 (03) : 337 - 340
  • [29] Intrapleural combination bevacizumab with cisplatin therapy for non-small cell lung cancer caused by non-small cell lung cancer
    Du, Nan
    Zhao, Hui
    Wang, Haibin
    Li, Xiaosong
    Ma, Junxun
    Fan, Zhongyi
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [30] Mutational profiling of the oncogenome in non-small cell lung cancer (NSCLC).
    Pao, W
    McLellan, MD
    Pham, DK
    Singh, B
    Rusch, VW
    Zakowski, MF
    Miller, VA
    Kris, MG
    Wilson, RK
    Varmus, HE
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 626S - 626S
12345